Metabolic and epigenetic reprogramming are key drivers of platinum resistance and disease recurrence in high-grade serous ovarian cancer (HGSC). The enzyme MAT2A synthesizes S-adenosylmethionine (SAM) from methionine; SAM is the universal methyl donor for DNA and histone methylation. Prior studies have linked altered SAM-dependent DNA methylation to acquired platinum resistance in HGSC, motivating investigation of whether MAT2A-driven SAM synthesis coordinates metabolic and epigenetic remodeling that impacts platinum sensitivity.
The authors report that upregulation of MAT2A correlated with poorer progression-free survival in ovarian cancer patients, as described in the preprint. This clinical association supported further mechanistic studies to test whether interfering with MAT2A could alter response to platinum chemotherapy.
Both pharmacological inhibition and genetic knockdown of MAT2A increased sensitivity to cisplatin in the experimental models presented. In vitro interventions targeting MAT2A enhanced platinum-induced cell death, indicating that MAT2A activity contributes to cellular resistance mechanisms against platinum agents.
To probe epigenetic mechanisms, the study profiled genome-wide DNA methylation in OVCAR3 cells treated with cisplatin (15 μM for 16 hours) and/or MAT2A siRNA (48 hours). MAT2A knockdown reversed platinum-induced DNA methylation dynamics, notably preventing platinum-induced promoter hypermethylation. Pathway analyses of methylation-altered regions showed enrichment for pathways linked to platinum resistance, DNA repair, and cellular stemness, implicating MAT2A-dependent methylation as a mediator of these phenotypes.
Mechanistically, inhibition of MAT2A abrogated activity along the SAMTOR–mTOR–S6K–FANCD2 signaling axis reported in the source. Disruption of this pathway was associated with accumulation of R-loops and attenuated activation of DNA repair signaling in response to platinum. The chain of events—reduced SAM availability, altered methylation, and impaired signaling—links metabolic perturbation to defects in genome maintenance after platinum exposure.
Using a functional DNA damage reporter assay, the investigators directly showed that MAT2A knockdown reduced DNA repair by both homologous recombination (HR) and non-homologous end joining (NHEJ). Detection of key DNA damage response kinases further demonstrated that MAT2A inhibition prevented activation of DNA repair signaling following platinum treatment. Collectively, these data indicate that MAT2A activity supports DNA damage response mechanisms that repair platinum-induced lesions; removing MAT2A function enhances platinum-induced DNA damage and cell death.
Single-sample Gene Set Enrichment Analysis (ssGSEA) of paired primary and recurrent HGSC tumors revealed an association between MAT2A expression and increased ovarian cancer stem cell (OCSC) features in recurrent tumors. Experimentally, MAT2A inhibition prevented cisplatin-induced enrichment of OCSCs in vitro, reduced expression of stemness markers, and decreased spheroid-forming ability. Importantly, these anti-stemness effects were rescued by exogenous SAM supplementation, indicating that the phenotypes depend on SAM availability downstream of MAT2A.
The preprint presents a mechanistic link between metabolism and epigenetic regulation: the MAT2A–SAM axis appears to enable platinum-induced DNA methylation remodeling, sustain DNA damage response signaling (including the SAMTOR–mTOR–S6K–FANCD2 axis), and promote OCSC enrichment. Targeting MAT2A or limiting SAM synthesis impaired HR and NHEJ repair, increased platinum-induced DNA damage and cell death, and prevented enrichment of OCSCs—suggesting MAT2A inhibition may sensitize HGSC to platinum chemotherapy and reduce OCSC-driven recurrence.
Limitations and caveats from the source: this work is reported as a preprint and has not undergone peer review. The abstract provides experimental endpoints and some treatment conditions (for example, cisplatin 15 μM for 16 hr and MAT2A siRNA for 48 hr), but the preprint abstract does not include full methodological detail, comprehensive statistical metrics, the identities or doses of pharmacologic MAT2A inhibitors used, or detailed cohort information for the clinical correlations. Those details were not reported in the abstract and would need to be consulted in the full manuscript or supplementary material for translational planning.
Overall, the findings described support further preclinical and translational evaluation of MAT2A or SAM-targeting strategies as adjuncts to platinum therapy in HGSC, with attention to validating the safety, dosing, and efficacy in more comprehensive models and eventual clinical testing.